Recent trends indicate that patients with non-ischemic dilated cardiomyopathy represent the largest subpopulation of heart failure patients with a significant need for alternative treatment modalities. Similar to ischemic cardiomyopathy, patients with non-ischemic dilated cardiomyopathy have been found to have myocardial regions with flow abnormalities, which may represent the targets for neoagiogenetic therapies. CD34(+) stem cells might contribute to the formation of new blood vessels from existing vascular structures in ischemic tissues by the direct incorporation of injected cells into the newly developing vasculature or the production and secretion of angiogenic cytokines. The review summarizes the long-term clinical effects and potential underlying mechanisms of CD34(+) cell therapy in patients with non-ischemic dilated cardiomyopathy.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 31 July 2013. doi:10.1038/clpt.2013.134.
[Show abstract][Hide abstract] ABSTRACT: Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly. It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget. HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension. Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF). However, treatment of HFpEF still poses significant challenges.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.